 Connection
Sandra Luna-Fineman to Cyclophosphamide
This is a "connection" page, showing publications Sandra Luna-Fineman has written about Cyclophosphamide.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.416 |
|
|
|
-
Luna-Fineman S, Castellanos M, Metzger ML, Baez LF, Peña Hernandez A, Bonilla M, Fuentes-Alabi S, Nieves R, Blanco J, Rossi E, Devidas M, Chen Y, Arreola M, de Alarcon PA. Treatment of high-risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes. Pediatr Blood Cancer. 2024 Feb; 71(2):e30792.
Score: 0.190
-
Graff Z, Giron V, Miller K, Pixtun D, Alejos A, Luna-Fineman S. Toxicity and feasibility of vincristine, etoposide, and carboplatin alternating with vincristine, doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala. Pediatr Blood Cancer. 2023 07; 70(7):e30392.
Score: 0.183
-
Garfin PM, Link MP, Donaldson SS, Advani RH, Luna-Fineman S, Kharbanda S, Porteus M, Weinberg KI, Agarwal-Hashmi R. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transplant. 2015 Feb; 21(2):326-34.
Score: 0.025
-
Quackenbush KE, Luna-Fineman S, Magee JF, Gundogan M, Golobi M, Irie T, Fernandez CV. Neuroblastoma involvement of the falx cerebri. Pediatr Blood Cancer. 2009 Dec 15; 53(7):1337-9.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|